Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01650935
Other study ID # 114
Secondary ID
Status Completed
Phase N/A
First received July 24, 2012
Last updated April 15, 2013
Start date September 2012
Est. completion date April 2013

Study information

Verified date April 2013
Source Shahid Beheshti University of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Oxalate restricted diet is routinely prescribed in clinical practice of nephrolithiasis patients with hyperoxaluria. The effect of dietary oxalate on urinary oxalate is however controversial. Some studies do not implicate dietary oxalate as a major risk factor for nephrolithiasis. The Dietary Approaches to Stop Hypertension (DASH) diet, which is high in fruits and vegetables, moderate in low-fat dairy products, and low in animal protein represents a novel potential means of kidney stone prevention. The effect of a DASH-style diet on relative urinary supersaturations is however uncertain. Higher consumption of fruits and vegetables may increase urinary oxalate but also increases urinary citrate, an important inhibitor of calcium saturation.All the above data lead us to hypothesize that a DASH diet other than an oxalate restricted diet, which is routinely administered in clinical practice, might be beneficial in lowering urinary relative supersaturations of calcium oxalate in recurrent stone formers with hyperoxaluria.

Recurrent stone formers with hyperoxaluria (urine oxalate>32.8) are allocated into 2 groups. The first group is prescribed an oxalate restricted diet. The second group are asked to follow a calorie-controlled DASH diet plan while drink water in the same amounts. 24-h urine is collected 2 times before study visits at baseline, 1 time on week 6 and 2 times at the end of the study.


Description:

After a run-in period of 3 weeks patients are allocated into 2 groups. The first group is prescribed an oxalate restricted diet. They are instructed to avoid oxalate-rich foods such as spinach, rhubarb, beets, chocolate, cereals, nuts, tea, wheat bran, and strawberries and to drink water in amounts of roughly 2 L during cold weather and 3 L during warm/hot weather. The second group is asked to follow a calorie-controlled DASH diet plan. DASH is an eating pattern recommended by the 2005 Department of Health and Human Services Dietary Guidelines for Americans as a model of healthy eating for the majority of individuals in the population . This group eats a diet which includes higher fruit, vegetables, and low-fat dairy products and lower in saturated fat, total fat, and cholesterol, containing more whole grains and fewer refined grains, sweets, and red meat. The calcium, potassium, and magnesium of the DASH diet is higher. The DASH diet contains 2,400 mg Na per day . The servings, mentioned in the publication of the National Institutes of Health regarding the DASH eating plan, are used as a practical guideline. Lower consumption of meat and higher consumption of low-fat dairies, vegetable, fruit, whole-grain cereals, and legumes distinguish between the DASH trial and the weight-reduction diet.

We determine the caloric needs for each person in both groups individually according to the Harris Benedict Formula:

Metric BMR Formula Women: BMR= 655 + ( 9.6 × weight in kilos ) + ( 1.8 × height in cm ) - ( 4.7 × age in years ) Men: BMR= 66 + ( 13.7 × weight in kilos ) + ( 5 × height in cm ) - ( 6.8 × age in years )

To determine their total daily calorie needs, multiply their BMR by the appropriate activity factor, as follows:

If they are sedentary (little or no exercise) : Calorie-Calculation = BMR × 1.2 If they are lightly active (light exercise/sports 1-3 days/week) : Calorie-Calculation = BMR × 1.375 If they are moderately active (moderate exercise/sports 3-5 days/week) : Calorie-Calculation = BMR × 1.55 If they are very active (hard exercise/sports 6-7 days a week) : Calorie-Calculation = BMR × 1.725 If they are extra active (very hard exercise/sports & physical job or 2x training) : Calorie-Calculation = BMR × 1.9

The patients are visited in the beginning, after 6 weeks and at the end of the study; each session for a patient is 45-60 min. They are in touch with the nutritionist by phone every week. The nutritionist explains the benefits of each diet for patients and tells them if they continue these diets, related metabolic abnormalities might be controlled. The diets are individually prescribed using a calorie count system, and an exchange list is given to each patient for exchanging food items and counting the calories. A nutritionist educates subjects on how to use the exchange list. Patient compliance to diet is evaluated by a detailed food recall for 3 days which are collected from 2 weekdays and 1 weekend day in week 1 and week 12 as well as evaluation of the urinary excretion of sodium, inorganic sulfate and total nitrogen. The food recalls are reviewed by a nutrition PhD when they are submitted and then are analyzed using nutritionist IV software. 24-h urine is also collected 2 times before study visits at baseline, and 2 times at the end of the study on the day food recalls are filled. Urinary supersaturation of calcium oxalate, calcium phosphate and uric acid also is calculated at the beginning and end of the study. Because this is a dietary intervention, patients are not blinded.

Clinical measurements included blood pressure, weight, height, and waist circumference. Blood pressure measurements are the average of 2 measurements and are taken using an automated system after the subjects are seated for 5 minutes. Participants are weighed wearing minimal clothing and without shoes. Height is measured in a standing position, without shoes. Waist circumference is measured where the waist is narrowest over light clothing. Body mass index (kg/m2) is calculated as weight (kg) divided by height squared (m2) We use General Linear Models (paired t tests) to globally compare means of all variables at the end of the 2 different diet periods with and without adjustment for weight. We calculate the percent change for each variable using the formula (E- B/B)×100, where E was the end of treatment value and B was the baseline value. Groups are compared using the percent change in the General Linear Model (paired t test)analyses. We use ANCOVA to compare adjusted means of end values and percent changes while weight change was included as a covariate. Results are considered significant if the 2-tailed P-value is<,0.05. Statistical analyses are performed using STATA 15.0.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date April 2013
Est. primary completion date February 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- A history of at least one time kidney stone

- more than 18 years old

- stones at least 50% calcium oxalate

- normal renal function, -sterile urine samples, -

- normal blood pressure

Exclusion Criteria:

- primary hyperoxaluria (urine oxalate>100 mg/24h)

- diabetes mellitus

- hepatic, thyroid, parathyroid, CKD or immunologic disease

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
diet
When the first set of urine samples confirmed hyperoxaluria (urine oxalate>32.8), the patients will enter the study. After a run-in period of 3 weeks patients are allocated into 2 groups that I already explained in the arms section.The patients are visited in the beginning, after 6 weeks and at the end of the study

Locations

Country Name City State
Iran, Islamic Republic of Labbafinejad Hospital Tehran
Iran, Islamic Republic of Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences Tehran

Sponsors (1)

Lead Sponsor Collaborator
Shahid Beheshti University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary urinary oxalate 24-h urine including urine oxalate is collected 2 times before study visits at baseline, and 2 times at the end of the study which is 2 months. 2 months
Secondary urinary calcium oxalate supersaturation Urinary supersaturation is calculated before study visits at baseline, and at the end of the study which is 2 months. 2 months
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04746378 - PRedictive Accuracy of Initial Stone Burden Evaluation.
Recruiting NCT05100017 - Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure N/A
Recruiting NCT03692715 - Antibiotic Prophylaxis Before Shock Wave Lithotripsy Phase 4
Completed NCT02547805 - Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days Phase 2
Completed NCT02289755 - Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria Phase 2
Completed NCT01690039 - Influence of Polymorphisms in the ATP6V1 Gene of the V-ATPase on the Development of Incomplete Distal Renal Tubular Acidosis
Completed NCT01295879 - Vitamin D Repletion in Stone Formers With Hypercalciuria Phase 4
Recruiting NCT05014178 - Kidney Sodium Functional Imaging
Not yet recruiting NCT06199102 - The High Initial Dose of Monitored Vitamin D Supplementation in Preterm Infants. N/A
Recruiting NCT04367155 - Efficacy of Tranexamic Acid on Blood Loss During Percutaneous Nephrolithotomy. N/A
Recruiting NCT04374188 - Efficacy of Ciprofloxacin Therapy in Avoidance of Sepsis in Patient Undergoing Percutanous Nephrolithotomy N/A
Recruiting NCT05701098 - SOUND Pivotal Trial - (Sonomotion stOne comminUtion resoNance ultrasounD) N/A
Recruiting NCT04389853 - Mini-PNCL vs fURS in Management of Nephrolithiasis N/A
Completed NCT03348228 - Effect of Hydroxycitrate on Urine Chemistry N/A
Completed NCT05350423 - Trial Assessing Renal Damage During Ureteroscopy N/A
Completed NCT03454139 - Subcostal TAP Block For Percutaneous Nephrolithotomy N/A
Recruiting NCT02279927 - Prospective Comparison Between Different Laser Settings for Ureteral \ Kidney Stones Treatment During Ureteroscopy N/A
Completed NCT02276924 - Diagnostic Relevance of Laser Confocal Microscopy for the Screening of Upper Urinary Tract Tumors N/A
Completed NCT00159393 - Percutaneous Nephrolithotomy: A Registry and Database
Completed NCT02878148 - Conditional Imaging Prescription Strategy for Exploration of Acute Uncomplicated Renal Colic N/A